Search

for
Search:

Glossary Benign Prostatic Hyperplasia

non-cancerous enlargement of the prostate gland common in older men

Benign Prostatic Hyperplasia (BPH), also known as an enlarged prostate, is a non-cancerous increase in the size of the prostate gland. This condition is common in older men and can lead to urinary symptoms such as difficulty starting urination, a weak urine stream, and frequent urination, especially at night. BPH occurs due to hormonal changes and can be managed with medications, lifestyle changes, or surgical procedures if necessary.

Related Terms

Research

5 / 1000+ results

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

235 citations , September 2004 in “The Journal of urology/The journal of urology”

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content

research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*

82 citations , February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.

Tamsulosin Treatment for Benign Prostatic Hyperplasia and Risk of Severe Hypotension in Men Aged 40-85 Years in the United States: Risk Window Analyses Using Between and Within Patient Methodology

research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology

70 citations , November 2013 in “The BMJ”

This study observed a temporal association between tamsulosin use for benign prostatic hyperplasia and an increased risk of severe hypotension requiring hospital admission during the first eight weeks of treatment initiation and restart.

View more "benign prostatic hyperplasia" in research →

Community Join

5 / 117 results

community If I was arrested, could I take minoxidil and finasteride in prison?

in Chat 1349 upvotes 1 year ago

Access to minoxidil and finasteride in prison is unlikely unless prescribed for medical conditions like hypertension or benign prostatic hyperplasia. Cosmetic treatments are generally not provided in prison.

community Evolution theory: AGA is your body trying to reduce the risk of prostate cancer by exposing your scalp to more UV

in Research/Science 9 months ago

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

community Dermatologist told me to quit fin after turning 40

in Finasteride/Dutasteride 194 upvotes 2 years ago

A dermatologist advised a patient to stop taking finasteride (fin) after turning 40 due to potential risk of aggressive prostate cancer. The patient and others in the conversation debated this advice, discussing the relationship between finasteride, prostate cancer, and hair loss, and considering alternatives like topical finasteride.

community Dutasteride takes 1-3 months to work in the scalp. Not weeks. Be careful.

in Finasteride/Dutasteride 41 upvotes 2 years ago

Dutasteride takes 1-3 months to affect scalp DHT levels, not just a week. The prostate absorbs Dutasteride faster than the scalp due to different vascular networks and enzyme densities.

community Serenoa repens (Saw palmetto)

3 upvotes 6 months ago

Saw palmetto, a 5-alpha reductase inhibitor, caused unexpected side effects like breast changes and altered semen consistency, which resolved after stopping its use. Concerns about similar side effects with finasteride or dutasteride were expressed, and another user reported low libido and depression from saw palmetto.

View more "benign prostatic hyperplasia" in community →

Learn

2 / 801 results

learn tamsulosin

What is tamsulosin and how is it used in treatments related to hair loss? Tamsulosin is a prescription alpha-1 blocker approved for benign prostatic hyperplasia; no human trial has tested it for hair loss, and there are no dosing protocols or safety data for that use. Its connection to hair is a receptor-biology hypothesis, not a treatment.

learn Saw Palmetto

a natural and far less effective alternative to Finasteride

View more "benign prostatic hyperplasia" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →